CA2458084A1 - Novel process for octreotide synthesis - Google Patents
Novel process for octreotide synthesis Download PDFInfo
- Publication number
- CA2458084A1 CA2458084A1 CA002458084A CA2458084A CA2458084A1 CA 2458084 A1 CA2458084 A1 CA 2458084A1 CA 002458084 A CA002458084 A CA 002458084A CA 2458084 A CA2458084 A CA 2458084A CA 2458084 A1 CA2458084 A1 CA 2458084A1
- Authority
- CA
- Canada
- Prior art keywords
- boc
- phe
- cys
- trt
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Abstract
A new hybrid solid phase-liquid phase method of Octreotide synthesis is invented. This method comprises liquid phase condensation of at least two peptide blocks, from which at least one is synthesized by solid-phase method . Every such block should contain two or more amino acid residues. The meth od of invention combines the time and labor effectiveness of the solid-phase method with relative cheapness and easiness of purification of the product, characteristic for the liquid-phase method.
Description
NOEL PROCESS FOR OCTREOTlDE SIrN°T~IESIS
Background of the invention Octreotide (OCT) is the active pharmaceutical ingredient of the drug Sandostatin, using in treatment of some cancer diseases, especially acromegaly etc.. it has the following chemical structure:
(D)-Phe-Cys-Phe-(D)-Trp-L ys-Thr-Cys-Thr-oh The described syntheses of OCT may be divided into three main approaches:
1) Direct solid-phase synthesis, comprising attachment of a C-terminal amino acid to a resin, and step-by step elongation of the peptide chain, with pre-activated amino acids. This route is expensive because it requires large excesses of starting amino acids and additionally is quite labor consuming and necessitates complex purification procedures to separate the product from the impurities since they are very similar to the final product. These shortcomings are especially important for large scale industrial production of the product. (CA 2309312AI;
US
6,476,186 B 1 ).
Background of the invention Octreotide (OCT) is the active pharmaceutical ingredient of the drug Sandostatin, using in treatment of some cancer diseases, especially acromegaly etc.. it has the following chemical structure:
(D)-Phe-Cys-Phe-(D)-Trp-L ys-Thr-Cys-Thr-oh The described syntheses of OCT may be divided into three main approaches:
1) Direct solid-phase synthesis, comprising attachment of a C-terminal amino acid to a resin, and step-by step elongation of the peptide chain, with pre-activated amino acids. This route is expensive because it requires large excesses of starting amino acids and additionally is quite labor consuming and necessitates complex purification procedures to separate the product from the impurities since they are very similar to the final product. These shortcomings are especially important for large scale industrial production of the product. (CA 2309312AI;
US
6,476,186 B 1 ).
2) Liquid-phase synthesis, comprising condensation of amino acids in solution.
Usually several blocks, containing from 2 to 5 amino acids were synthesized independently and after that these synthons were condensed to each other in the required sequence. (WO 0310971668; US 4,395,403; f~U 2196144 C1 ).
The advantage of this kind of processes is that it is less expensive than the previous one and the product is easier to purify. This method is also more effective for scale-up. A drawback is that the method is much more labor and time consuming.
Usually several blocks, containing from 2 to 5 amino acids were synthesized independently and after that these synthons were condensed to each other in the required sequence. (WO 0310971668; US 4,395,403; f~U 2196144 C1 ).
The advantage of this kind of processes is that it is less expensive than the previous one and the product is easier to purify. This method is also more effective for scale-up. A drawback is that the method is much more labor and time consuming.
3) A hybrid solid phase-liquid phase method comprising formation of fragments of the target amino acid sequence by solid-phase synthesis and after that liquid phase condensation of this block with required supplE:mentary amino acid or another block. Only one OCT synthesis of this type was described in the literature, where on the final step the modified amino acid threoninol was condensed in solution with a 7-mer that had been obtained by solid-phase synthesis (US patent 6,346,601 ). This method is a blend of the first two, combining the time and labor effectiveness of the solid-phase method with relative cheapness and easiness of purification of thE; product, characteristic for the liquid-phase method.
Summary of the invention This invention provides a new, more cost-effective and labor-saving method for obtaining OCT and its pharmaceutically acceptable salts by means of hybrid solid-phase - liquid-phase synthesis, wherein it comprises the liquid phase condensation of several peptide blocks obtained by solid-phase synthesis, containing more than one amino acid residue in every block, followed by formation of a disulfide bridge from two cysteine groups.
Generally, the methods of invention comprise synthesizing specific side-chain protected peptide fragment intermediates of OCT on a solid support or in solution, coupling of the protected fragments in solution to form a protected OCT, followed by deprotection of the side chains and oxidation to yield the final OCT.
The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the OCT.
Detailed description of the invention The main object of the present invention is to provide a new method for synthesis of octreotide. The octreotide has been synthesized by condensation of two or three fragments in solution. At least one of these fragments is synthesized by solid phase synthesis, whereas any of the other fragments could be synthesized also by a liquid phase method. The examples of such fragments are shown below Fmoc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp{Boc)-OH (I) Boc-(D)-Phe-Cys(Trt}-Phe-(D)-Trp{Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of (III) Fmoc-{D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-C>H (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OI-I {V) NH2-Thr(tBu)-Cys{Trt)-Thr{tBu)-of (VI) Fmoc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-T~hr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-{D)-Trp{Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-of (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of (XII) The solid phase synthesis of short fragments containing less than 3 amino acid residues is economically not expedient, therefore the preferred embodiment of the invention comprises the fragments synthesized by solid phase method containing more than 2 amino acid residues.
The side-chains of the amino acid residues of peptide fragments may be protected with standard protecting groups such as t-Butyl, trityl, Boc, Acm.
The tBu group is preferred side-chain protecting group for amino acid residues Thr and threoninol; the Trt and Acm groups are preferred side-chain protecting groups for Cys; the Boc group is preferred side-chain protecting group for amino acid residues Lys and Trp.
Resin loading can be performed via reaction of excess of an amino acid or an amino alcohol and super acid sensitive resin (for exarr~ple, 2-chlorotrityl chloride resin) in the presence of amine.
Standard Fmoc protocols can be used for synthesis of~ the fragments.
Removal of the Fmoc protecting group from the terminal amine group can be accomplished by treating the resin with piperidine solution in DMF. The protected amino acid may be activated through the reaction with condensing agents well-known to those skilled in the art (such as HBTU or TBTU).
Coupling completion may be monitored with a qualitative ninhydrin test.
The peptide fragments synthesized via solid phase synthesis techniques can be cleaved by acidic treatment of the peptidyl-resin with dilute solution of acid. The preferred acids for this purpose are TFA or HCI.
The cleaved peptide fragments can be coupled in the solution through activation of the N-terminal fragment carrying alpha-amino protecting group (Boc or Fmoc for example) with an appropriate coupling agent. The preferred coupling agents are HBTU or TBTU, though other usually used agent; might be chosen for this transformation.
The protected octapeptide can be precipitated by the addition of water and collected by vacuum filtration.
The final deprotection of the OCT can be done by treatment of the protected peptide with the solution of acid, preferred acid is TFA.
The cyclic product could be obtained by reaction of linear peptide with an appropriate reagent (for example hydrogen peroxide or iodine) in a buffer solution.
Crude product could be purified by using reverse phase, normal-phase or ion-exchange chromatography.
Examples Example 1: Fmoc-Thr('tBu)-ol-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS
reactor and washed with 250 ml of DCM. The bed was drained and a solution of Fmoc-Thr(tBu)-of (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added. The mixture was agitated with nitrogen bubbling for 2 hrs.
The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 mi of DCM, dried with an argon purge to give 34.4 g of loaded resin Example 2: Fmoc-(D)-Trp(Boc)-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS
reactor and washed with 250 ml of DCM. The bed was drained and a solution of Fmoc-(D)Trp(Boc)-OH (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added. The mixture was agitated with nitrogen bubbling for 2 hrs.
The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
Example 3: Solid phase synthesis of the peptide fr~gmenf Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of The 500 ml SPS reactor was charged 20.0 g of Fmoc~~T'hr(tBu)-ol-2-chlorotrityl resin. The resin was conditioned in 200m1 of DCM witll nitrogen agitation for about 15 min to swell the beads, and then drained.
Removal of the Fmoc protecting group from the terminal amine was accomplished by treating the resin with 2 aliquots of 20% solution piperidine in DMF. The resin is then washed 5-7 times with aliquots of DMF to remove the Fmoc by-products.
Fmoc-Cys(Trt)-OH was activated as follows. The Fmoc-protected amino acid (2 eq), 1-hydroxybenzotriazole hydrate (HOBT) (2 eq) and DIPEA (4 eq) were dissolved in NMP (about 10 volumes) at rt. The solution is chilled to 0-5°C and then HBTU {2 eq) is added followed by stirring for 5-15 rnin to dissolve. The solution of activated amino acid was added to the drained resin and the reaction was agitated with argon bubbling for about 1 hr. Coupling completion may be monitored with a qualitative ninhydrin test.
The cycle was repeated for Fmoc-Thr(tBu)-OH and Fmoc-Lys{Boc)-OH.
Following the final coupling reaction and washings the deprotection step was performed and the resin was washed with DMA, DCM. The resin was dried with an argon purge to give 36 g resin-bond peptide.
The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM
for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine {1:1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min. The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 15 g of the peptide fragmE:nt.
Example 4: Solid phase synthesis of the peptide fn~~ment Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-(~H
Procedure The 500 ml SPS reactor was charged with 20.0 g of Fmoc-(D)-Trp(Boc)-2-chlorotrityl resin. The resin was conditioned in 200m1 of DCM with nitrogen agitation for about 15 min to swell the beads, and then drained.
After Fmoc removal, Fmoc-Phe-OH was activated as described above.
The cycle was repeated for Fmoc-Cys{Trt)-OH and Boc-(D)-Phe-OH. Following the final coupling reaction and washings the resin was dried with an argon purge to give 38 g resin-bond peptide.
The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM
for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine (1:1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min. The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 17 g of the peptide fragment.
Example 5: Synthesis of Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of A 25 ml round bottom flask containing a magnetic stir bar was charged with Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol, Boc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp(Boc)-OH and HOBt. The solids were dissolved in 9:1 DMA:DMSO (5 ml) containing DIPEA, and then cooled to 0-5oC under nitrogen. To the cool solufiion HBTU was added. The reaction mixture was stirred for 15 min, then warmed up to room temperature and stirred an additional 60 min. The peptide was precipitated from the solution by addition of water, 7 ml. The solid was collected by filtration, washed with water and dried give 0.30 g of Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol.
Example 6: Synthesis of (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol.
Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of was cleaved with the mixture 95%TFA-2.5%EDT-2.5%H20 at room temperature for 2 hours. The cleavage solution was filtered, the resin was washed with TFA.
The combined washings were concentrated under vacuum to volume 0.5-1 ml followed by addition of 10 volumes of cold ether. The pellets were collected by centrifugation and washed with cold ether. The product was extracted with 50%
ACN and dried by lyophilization.
Example 7: Synthesis of Octreotide (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-of was dissolved in water at concentration 100 mglL. The pH of the solution was adjusted with 10 % NaOH to 8Ø 0.5 ml of H202 was added to the solution. The reaction mixture was stirred for 2 hrs, lyophilized. The crude product was purified b~y reverse phase HPLC
and ion-exchange LC.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Dalton Chemical Laboratories Inc.
(B) STREET: 349 Wildcat Road (C) CITY: Toronto (D) STATE/PROVINCE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE/ZIP: M3J 2S3 (ii) TITLE OF INVENTION: Process For Octreotide Synthesis (iii) NUMBER OF SEQUENCES: 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Borden Ladner Gervais LLP
(B) STREET: 1100-100 Queen Street (C) CITY: Ottawa (D) STATE/PROVINCE: Ontario (E) COUNTRY: CANADA
(F) POSTAL CODE/ZIP: K1P 1J9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy Disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Ver. 3.3 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,458,084 (B) FILING DATE: 12-MAR-2004 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Marsman, Kathleen E.
(B) REGISTRATION NUMBER: 10972 (C) REFERENCE/DOCKET NUMBER: PAT 2260-1 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613) 237-5160 (B) TELEFAX: (613) 787-3558 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic Peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Trp(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Xaa Cys Phe Xaa (2) INFORMATION FOR SEQ ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic Peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
xaa Cys Phe xaa (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Lys(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 3:
Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Xaa Cys Phe Xaa Lys (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Xaa Cys Phe Xaa Lys (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(BoC) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (6). (6) (D) OTHER INFORMATION: Thr(tBu)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Xaa Cys Phe Xaa Lys Thr (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (1x) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(BoC) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (6). (6) (D) OTHER INFORMATION: Thr(tBu)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 8:
Xaa Cys Phe Xaa Lys Thr (2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 9:
Cys Thr (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Phe-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Xaa Cys Phe (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Phe-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 11:
Xaa Cys Phe (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Trp(boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Lys(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 12:
Trp Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID N0: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_ (2). (2) (D) OTHER
INFORMATION:
Cys(Trt) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
Summary of the invention This invention provides a new, more cost-effective and labor-saving method for obtaining OCT and its pharmaceutically acceptable salts by means of hybrid solid-phase - liquid-phase synthesis, wherein it comprises the liquid phase condensation of several peptide blocks obtained by solid-phase synthesis, containing more than one amino acid residue in every block, followed by formation of a disulfide bridge from two cysteine groups.
Generally, the methods of invention comprise synthesizing specific side-chain protected peptide fragment intermediates of OCT on a solid support or in solution, coupling of the protected fragments in solution to form a protected OCT, followed by deprotection of the side chains and oxidation to yield the final OCT.
The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the OCT.
Detailed description of the invention The main object of the present invention is to provide a new method for synthesis of octreotide. The octreotide has been synthesized by condensation of two or three fragments in solution. At least one of these fragments is synthesized by solid phase synthesis, whereas any of the other fragments could be synthesized also by a liquid phase method. The examples of such fragments are shown below Fmoc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp{Boc)-OH (I) Boc-(D)-Phe-Cys(Trt}-Phe-(D)-Trp{Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of (III) Fmoc-{D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-C>H (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OI-I {V) NH2-Thr(tBu)-Cys{Trt)-Thr{tBu)-of (VI) Fmoc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-T~hr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-{D)-Trp{Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-of (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of (XII) The solid phase synthesis of short fragments containing less than 3 amino acid residues is economically not expedient, therefore the preferred embodiment of the invention comprises the fragments synthesized by solid phase method containing more than 2 amino acid residues.
The side-chains of the amino acid residues of peptide fragments may be protected with standard protecting groups such as t-Butyl, trityl, Boc, Acm.
The tBu group is preferred side-chain protecting group for amino acid residues Thr and threoninol; the Trt and Acm groups are preferred side-chain protecting groups for Cys; the Boc group is preferred side-chain protecting group for amino acid residues Lys and Trp.
Resin loading can be performed via reaction of excess of an amino acid or an amino alcohol and super acid sensitive resin (for exarr~ple, 2-chlorotrityl chloride resin) in the presence of amine.
Standard Fmoc protocols can be used for synthesis of~ the fragments.
Removal of the Fmoc protecting group from the terminal amine group can be accomplished by treating the resin with piperidine solution in DMF. The protected amino acid may be activated through the reaction with condensing agents well-known to those skilled in the art (such as HBTU or TBTU).
Coupling completion may be monitored with a qualitative ninhydrin test.
The peptide fragments synthesized via solid phase synthesis techniques can be cleaved by acidic treatment of the peptidyl-resin with dilute solution of acid. The preferred acids for this purpose are TFA or HCI.
The cleaved peptide fragments can be coupled in the solution through activation of the N-terminal fragment carrying alpha-amino protecting group (Boc or Fmoc for example) with an appropriate coupling agent. The preferred coupling agents are HBTU or TBTU, though other usually used agent; might be chosen for this transformation.
The protected octapeptide can be precipitated by the addition of water and collected by vacuum filtration.
The final deprotection of the OCT can be done by treatment of the protected peptide with the solution of acid, preferred acid is TFA.
The cyclic product could be obtained by reaction of linear peptide with an appropriate reagent (for example hydrogen peroxide or iodine) in a buffer solution.
Crude product could be purified by using reverse phase, normal-phase or ion-exchange chromatography.
Examples Example 1: Fmoc-Thr('tBu)-ol-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS
reactor and washed with 250 ml of DCM. The bed was drained and a solution of Fmoc-Thr(tBu)-of (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added. The mixture was agitated with nitrogen bubbling for 2 hrs.
The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 mi of DCM, dried with an argon purge to give 34.4 g of loaded resin Example 2: Fmoc-(D)-Trp(Boc)-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS
reactor and washed with 250 ml of DCM. The bed was drained and a solution of Fmoc-(D)Trp(Boc)-OH (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added. The mixture was agitated with nitrogen bubbling for 2 hrs.
The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
Example 3: Solid phase synthesis of the peptide fr~gmenf Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of The 500 ml SPS reactor was charged 20.0 g of Fmoc~~T'hr(tBu)-ol-2-chlorotrityl resin. The resin was conditioned in 200m1 of DCM witll nitrogen agitation for about 15 min to swell the beads, and then drained.
Removal of the Fmoc protecting group from the terminal amine was accomplished by treating the resin with 2 aliquots of 20% solution piperidine in DMF. The resin is then washed 5-7 times with aliquots of DMF to remove the Fmoc by-products.
Fmoc-Cys(Trt)-OH was activated as follows. The Fmoc-protected amino acid (2 eq), 1-hydroxybenzotriazole hydrate (HOBT) (2 eq) and DIPEA (4 eq) were dissolved in NMP (about 10 volumes) at rt. The solution is chilled to 0-5°C and then HBTU {2 eq) is added followed by stirring for 5-15 rnin to dissolve. The solution of activated amino acid was added to the drained resin and the reaction was agitated with argon bubbling for about 1 hr. Coupling completion may be monitored with a qualitative ninhydrin test.
The cycle was repeated for Fmoc-Thr(tBu)-OH and Fmoc-Lys{Boc)-OH.
Following the final coupling reaction and washings the deprotection step was performed and the resin was washed with DMA, DCM. The resin was dried with an argon purge to give 36 g resin-bond peptide.
The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM
for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine {1:1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min. The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 15 g of the peptide fragmE:nt.
Example 4: Solid phase synthesis of the peptide fn~~ment Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-(~H
Procedure The 500 ml SPS reactor was charged with 20.0 g of Fmoc-(D)-Trp(Boc)-2-chlorotrityl resin. The resin was conditioned in 200m1 of DCM with nitrogen agitation for about 15 min to swell the beads, and then drained.
After Fmoc removal, Fmoc-Phe-OH was activated as described above.
The cycle was repeated for Fmoc-Cys{Trt)-OH and Boc-(D)-Phe-OH. Following the final coupling reaction and washings the resin was dried with an argon purge to give 38 g resin-bond peptide.
The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM
for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine (1:1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min. The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 17 g of the peptide fragment.
Example 5: Synthesis of Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of A 25 ml round bottom flask containing a magnetic stir bar was charged with Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol, Boc-(D)-Phe-Cys{Trt)-Phe-(D)-Trp(Boc)-OH and HOBt. The solids were dissolved in 9:1 DMA:DMSO (5 ml) containing DIPEA, and then cooled to 0-5oC under nitrogen. To the cool solufiion HBTU was added. The reaction mixture was stirred for 15 min, then warmed up to room temperature and stirred an additional 60 min. The peptide was precipitated from the solution by addition of water, 7 ml. The solid was collected by filtration, washed with water and dried give 0.30 g of Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol.
Example 6: Synthesis of (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol.
Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-of was cleaved with the mixture 95%TFA-2.5%EDT-2.5%H20 at room temperature for 2 hours. The cleavage solution was filtered, the resin was washed with TFA.
The combined washings were concentrated under vacuum to volume 0.5-1 ml followed by addition of 10 volumes of cold ether. The pellets were collected by centrifugation and washed with cold ether. The product was extracted with 50%
ACN and dried by lyophilization.
Example 7: Synthesis of Octreotide (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-of was dissolved in water at concentration 100 mglL. The pH of the solution was adjusted with 10 % NaOH to 8Ø 0.5 ml of H202 was added to the solution. The reaction mixture was stirred for 2 hrs, lyophilized. The crude product was purified b~y reverse phase HPLC
and ion-exchange LC.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Dalton Chemical Laboratories Inc.
(B) STREET: 349 Wildcat Road (C) CITY: Toronto (D) STATE/PROVINCE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE/ZIP: M3J 2S3 (ii) TITLE OF INVENTION: Process For Octreotide Synthesis (iii) NUMBER OF SEQUENCES: 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Borden Ladner Gervais LLP
(B) STREET: 1100-100 Queen Street (C) CITY: Ottawa (D) STATE/PROVINCE: Ontario (E) COUNTRY: CANADA
(F) POSTAL CODE/ZIP: K1P 1J9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy Disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Ver. 3.3 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,458,084 (B) FILING DATE: 12-MAR-2004 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Marsman, Kathleen E.
(B) REGISTRATION NUMBER: 10972 (C) REFERENCE/DOCKET NUMBER: PAT 2260-1 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613) 237-5160 (B) TELEFAX: (613) 787-3558 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic Peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Trp(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Xaa Cys Phe Xaa (2) INFORMATION FOR SEQ ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic Peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
xaa Cys Phe xaa (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Lys(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 3:
Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Xaa Cys Phe Xaa Lys (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(Boc)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Xaa Cys Phe Xaa Lys (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(BoC) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (6). (6) (D) OTHER INFORMATION: Thr(tBu)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Xaa Cys Phe Xaa Lys Thr (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (1x) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)Trp(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Lys(BoC) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (6). (6) (D) OTHER INFORMATION: Thr(tBu)-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 8:
Xaa Cys Phe Xaa Lys Thr (2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 9:
Cys Thr (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Fmoc-(D)Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Phe-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Xaa Cys Phe (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Phe-OH
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 11:
Xaa Cys Phe (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: NH2-Trp(boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (2). (2) (D) OTHER INFORMATION: Lys(Boc) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (3). (3) (D) OTHER INFORMATION: Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (5). (5) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 12:
Trp Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID N0: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: Boc-(D)-Phe (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_ (2). (2) (D) OTHER
INFORMATION:
Cys(Trt) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
(4). (4) (D) OTHER
INFORMATION:
Trp(Boc) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
INFORMATION:
Trp(Boc) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
(5). (5) (D) OTHER
INFORMATION:
Lys(Boc) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
INFORMATION:
Lys(Boc) (ix) FEATURE:
(A) NAME/KEY:MISC
FEATURE
(B) LOCATION:_
(6). (6) (D) OTHER
INFORMATION:
Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (7). (7) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
Xaa Cys Phe Xaa Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID N0: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: (D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 14:
Xaa Cys Phe Xaa Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: (D)-Phe (ix) FEATURE:
(A) NAME/KEY: DISULFID
(B) LOCATION: (2)..(7) (D) OTHER INFORMATION: A disulfide bridge is in place between the Cys residues (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Xaa Cys Phe Xaa Lys Thr Cys Thr
INFORMATION:
Thr(tBu) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (7). (7) (D) OTHER INFORMATION: Cys(Trt) (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr(tBu)-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
Xaa Cys Phe Xaa Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID N0: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: (D)-Phe (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr-of (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 14:
Xaa Cys Phe Xaa Lys Thr Cys Thr (2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial (ix) FEATURE:
(D) OTHER INFORMATION: Synthetic peptide (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (1). (1) (D) OTHER INFORMATION: (D)-Phe (ix) FEATURE:
(A) NAME/KEY: DISULFID
(B) LOCATION: (2)..(7) (D) OTHER INFORMATION: A disulfide bridge is in place between the Cys residues (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (4). (4) (D) OTHER INFORMATION: (D)-Trp (ix) FEATURE:
(A) NAME/KEY: MISC_FEATURE
(B) LOCATION: (8). (8) (D) OTHER INFORMATION: Thr-of (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Xaa Cys Phe Xaa Lys Thr Cys Thr
Claims (27)
1. A process for obtaining octreotide or a pharmaceutically acceptable salt thereof by hybrid solid-phase - liquid-phase synthesis, comprising the steps of:
condensing two or three peptide blocks using liquid phase condensation to form a condensation product, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis, and wherein the condensation product comprises in sequence the amino acids residues of octreotide; and cyclizing the condensation product to form a disulfide bridge between two cysteine residues.
condensing two or three peptide blocks using liquid phase condensation to form a condensation product, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis, and wherein the condensation product comprises in sequence the amino acids residues of octreotide; and cyclizing the condensation product to form a disulfide bridge between two cysteine residues.
2. The process of claim 1 wherein two peptide blocks are condensed in the step of condensing.
3. The process of claim 1 or 2, wherein one peptide block synthesized by solid-phase synthesis contains at least three amino acid residues.
4. The process of claim 3, wherein one peptide block synthesized by solid-phase synthesis contains at least four amino acid residues.
5. The process of any one of claims 1 to 4, wherein solid phase synthesis is performed on super acid sensitive resin.
6. The process of claim 5, wherein the super acid sensitive resin is CTC
resin.
resin.
7. The process of any one of claims 1 to 6, wherein the step of condensing is accomplished by use of HBTU, TBTU or HATU as a condensation agent.
8. The process of any one of claims 1 to 7, wherein an a-amino group on at least one peptide block is protected with a Boc or Fmoc protecting group.
9. The process of any one of claims 1 to 8, wherein a side-chain of at least one amino acid residue of at least one peptide block is protected with a t-Butyl, Trityl, Boc, or Acm protecting group.
10. The process of any one of claims 1 to 19, wherein the step of cyclizing is accomplished by action of an oxidative reagent.
11. The process of claim 10, wherein the oxidative reagent is hydrogen peroxide or iodine.
12. The process of any one of claims 1 to 11, wherein at least one of the peptide blocks is selected from the group consisting of:
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V) NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V) NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
13. The process of any one of claims 1 to 11 wherein the step of condensing comprises condensing two peptide blocks formed using solid phase synthesis, the peptide blocks having the following amino acid residues:
(D)-Phe-Cys-Phe-(D)-Trp and Lys-Thr-Cys-Thr-ol.
(D)-Phe-Cys-Phe-(D)-Trp and Lys-Thr-Cys-Thr-ol.
14. The process of claim 12 wherein the two peptide blocks are:
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) and NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III).
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) and NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III).
15. The process of claim 14 wherein the peptide block Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) is prepared by forming a protected resin:
Fmoc-(D)-Trp(Boc)-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin to form Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-CTC-resin; and cleaving the peptide block from the resin.
Fmoc-(D)-Trp(Boc)-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin to form Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-CTC-resin; and cleaving the peptide block from the resin.
16. The process of claim 14 wherein the peptide block NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) is prepared by forming a protected resin:
Fmoc-Thr(tBu)-ol-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin; and cleaving the peptide block from the resin.
Fmoc-Thr(tBu)-ol-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin; and cleaving the peptide block from the resin.
17. The process of claim 2 wherein the two peptide blocks are prepared using solid-phase synthesis.
18. A process for obtaining an intermediate in octreotide synthesis by hybrid solid-phase - liquid-phase synthesis, comprising the steps of:
obtaining two or three peptide blocks, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis;
condensing the peptide blocks using liquid phase condensation to form a condensation product, wherein the condensation product comprises in sequence the amino acids residues of octreotide.
obtaining two or three peptide blocks, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis;
condensing the peptide blocks using liquid phase condensation to form a condensation product, wherein the condensation product comprises in sequence the amino acids residues of octreotide.
19. The process of claim 18 wherein two peptide blocks are condensed in the step of condensing.
20. The process of claim 18 or 19, wherein one peptide block synthesized by solid-phase synthesis contains at least three amino acid residues.
21. The process of claim 20, wherein one peptide block synthesized by solid-phase synthesis contains at least four amino acid residues.
22. The process of any one of claims 18 to 21, wherein solid phase synthesis is performed on super acid sensitive resin.
23. The process of claim 22, wherein the super acid sensitive resin is CTC
resin.
resin.
24. The process of any one of claims 18 to 23, wherein the step of condensing is accomplished by use of HBTU, TBTU or HATU as a condensation agent.
25. The process of any one of claims 18 to 24, wherein an a-amino group on at least one peptide block is protected with a Boc or Fmoc protecting group.
26. The process of any one of claims 18 to 25, wherein a side-chain of at least one amino acid residue of at least one peptide block is protected with a t-Butyl, Trityl, Boc, or Acm protecting group.
27. The process of any one of claims 18 to 26, wherein at least one of the peptide blocks is selected from the group consisting of:
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V) NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (II) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V) NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002458084A CA2458084A1 (en) | 2004-03-12 | 2004-03-12 | Novel process for octreotide synthesis |
| PCT/CA2005/000378 WO2005087794A1 (en) | 2004-03-12 | 2005-03-14 | Process for octreotide synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002458084A CA2458084A1 (en) | 2004-03-12 | 2004-03-12 | Novel process for octreotide synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2458084A1 true CA2458084A1 (en) | 2005-09-12 |
Family
ID=34975525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002458084A Abandoned CA2458084A1 (en) | 2004-03-12 | 2004-03-12 | Novel process for octreotide synthesis |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2458084A1 (en) |
| WO (1) | WO2005087794A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132505A1 (en) | 2012-03-09 | 2013-09-12 | Natco Pharma Limited | Improved process for preparation of octreotide by solution phase peptide synthesis |
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377891B2 (en) | 2008-11-07 | 2013-02-19 | Usv, Ltd. | Process for synthesis of cyclic octapeptide |
| PE20120425A1 (en) | 2009-01-23 | 2012-05-03 | Jackson H M Found Military Med | METHODS AND COMPOSITIONS BASED ON TYPE 2 PROTEIN OF SHIGA TOXIN |
| US20140296144A1 (en) | 2011-09-30 | 2014-10-02 | Mylan Laboratories, Ltd. | Process for the preparation of octreotide acetate |
| US9388212B2 (en) | 2013-02-21 | 2016-07-12 | Chemical & Biopharmaceutical Laboratories Of Patras S.A. | Solid phase peptide synthesis via side chain attachment |
| CN102850438B (en) * | 2012-09-19 | 2014-11-05 | 上海昂博生物技术有限公司 | Solid phase preparation method of crude octrotide |
| JP6382488B2 (en) * | 2013-02-21 | 2018-08-29 | ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． | Solid phase peptide synthesis via side chain bonds |
| WO2017175107A1 (en) * | 2016-04-04 | 2017-10-12 | Emcure Pharmaceuticals Limited | Process for preparation of octreotide acetate |
| CN117534728A (en) * | 2024-01-10 | 2024-02-09 | 哈尔滨吉象隆生物技术有限公司 | Preparation method of octreotide trisulfide bond impurity E |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2144357B1 (en) * | 1998-01-29 | 2000-12-16 | Lipotec Sa | PROCEDURE FOR OBTAINING THE SOMATOSTATINA OCTREOTIDE ANALOG. |
| US6476186B1 (en) * | 2000-05-23 | 2002-11-05 | Institute Of Nuclear Energy Research | Process for preparing octreotide and derivatives thereof |
| EP1506219A2 (en) * | 2002-05-22 | 2005-02-16 | Nishith C. Chaturvedi | Novel process for production of the somatostatin analog, octreotide |
-
2004
- 2004-03-12 CA CA002458084A patent/CA2458084A1/en not_active Abandoned
-
2005
- 2005-03-14 WO PCT/CA2005/000378 patent/WO2005087794A1/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132505A1 (en) | 2012-03-09 | 2013-09-12 | Natco Pharma Limited | Improved process for preparation of octreotide by solution phase peptide synthesis |
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005087794A1 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4405594B2 (en) | Improved solid phase peptide synthesis and reagents for use in such synthesis | |
| US6008058A (en) | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis | |
| WO2005087794A1 (en) | Process for octreotide synthesis | |
| US4786684A (en) | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis | |
| AU744812B2 (en) | Process for the preparation of resin-bound cyclic peptides | |
| CN109195618A (en) | Method for synthesizing 4 β of α, 7 peptide antagonists | |
| CN101899092B (en) | Novel peptide-link base-conjugate and solid phase synthesis method thereof | |
| KR20170026326A (en) | Method for preparing amg 416 | |
| KR100237126B1 (en) | Rapid synthesis and screening of peptide mimetics | |
| KR20130127443A (en) | Process for the manufacture of degarelix and its intermediates | |
| US8377891B2 (en) | Process for synthesis of cyclic octapeptide | |
| AU2014282839B9 (en) | Peptide-resin conjugate and use thereof | |
| WO2020254479A1 (en) | Process for the manufacture of glucagon | |
| TW200806686A (en) | Producing method of thioester compound of peptide | |
| JP2003519629A (en) | Use of non-peptide constrained mimetics of dipeptides or tripeptides in the synthesis of oligomers and artificial proteins and polypeptides | |
| EP3205664A1 (en) | Method for preparation of liraglutide using bal linker | |
| US6448031B1 (en) | Process for producing LH-RH derivatives | |
| CN100357313C (en) | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same | |
| CN114945580B (en) | Method for synthesizing south Ji Botai | |
| Cavallaro et al. | Solid‐phase synthesis of a dendritic peptide related to a retinoblastoma protein fragment utilizing a combined boc‐and fmoc‐chemistry approach | |
| JPWO2007043615A1 (en) | Peptide ester reagents and their use for the production of ligation or thioester compounds | |
| JPH06336496A (en) | Cyclic hexapeptide, its production and production of cyclic peptide | |
| Stasiak et al. | Peptides derived from α-hydroxymethylserine: Aspects of solid-phase synthesis | |
| JPH1067796A (en) | Synthesis of cyclic peptide | |
| CN115433266A (en) | Solid-phase synthesis method of teriparatide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |